A Case of COVID-19 with Acute Exacerbation after Anti-Inflammatory Treatment

Reports

Kokichi Ando¹  Yumiko Sakurada¹  Noriko Miyakawa²  Satoshi Yamanouchi²  Masahiro Yaegashiwa³  Yugo Ashino³  Yoichi Shirato³  Haorile Chagan Yasutan⁴  Toshio Hattori⁵ 

[1] Department of Anesthesiology, Sendai City Hospital, Miyagi 982-8502, Japan;Department of Emergency, Sendai City Hospital, Miyagi 982-8502, Japan;Department of Respiratory Medicine, Sendai City Hospital, Miyagi 982-8502, Japan;Mongolian Psychosomatic Medicine Department, International Mongolian Medicine Hospital of Inner Mongolia, Hohhot 010065, China;Research Institute of Health and Welfare, Kibi International University, Takahashi 716-8508, Japan;

关键词: COVID-19;    Galectin-9;    SARS-CoV-2;    acute exacerbation;    tocilizumab (TCZ);    acute respiratory distress (ARDS);   

DOI  :  10.3390/reports5020024

来源: DOAJ

【 摘 要 】

A COVID-19 patient (53-year-old woman from Japan) was admitted to our hospital. She had a high fever (38.3 °C), cough, fatigue, and loss of appetite. She was a smoker and took migraine medication. A thoracic computed tomography (CT) scan showed no evidence of pneumonia. She was treated with antibiotics, protease inhibitors, inhalant corticosteroids, and antivirals. Anti-interleukin-6 receptor antibody tocilizumab (TCZ 400 mg) was added on day 2. On day 4, her temperature decreased, but her vital signs suddenly worsened, with an SpO₂ of 70% in ambient air, a blood pressure of 70 mmHg (systolic), loss of consciousness, and tachypnea. Her CT showed bilateral lung consolidation and no pulmonary embolism. She was connected to the ventilator. On day 11, her respiratory condition improved (PaO₂/FIO₂ 400), and she was able to withdraw from the ventilator. Her laboratory data (white cell count, ferritin, d-Dimer, C-reactive protein, and β₂-microglobulin) did not increase even at the time of exacerbation, except for Galectin-9 (Gal-9). The plasma Gal-9 levels increased 2.3 times from before the administration of TCZ, followed by a swift decrease associated with improvements in respiratory status. She was discharged on day 16. Patients with TCZ-treated COVID-19 require careful observation.

【 授权许可】

Unknown